Destroying the “slime” that renders antibiotics useless
PreSeed Now profiles AURApeutics, its founder journey and the strategy of giving established antibiotics a new ultrasound-activated delivery modality.
Read at PreSeed NowFollow AURApeutics as the science moves beyond the bench—through international recognition, independent coverage and the milestones shaping our path to patients.
See what is making waves
AURApeutics has been selected for the Falling Walls Venture Top 100, an international list of science-led companies turning research into business. The 2026 cohort spans health, engineering and sustainability.
Explore the 2026 shortlistPreSeed Now profiles AURApeutics, its founder journey and the strategy of giving established antibiotics a new ultrasound-activated delivery modality.
Read at PreSeed NowVictor Choi was a finalist and won the Best Pitch Prize after presenting AURApeutics to more than 200 investors and deep-tech stakeholders in London.
View the founder updateUniversity of Oxford coverage details ultrasound-activated antibiotic nanoparticles designed to disrupt biofilms and release treatment directly at the infection site.
Read the Oxford storyBorn to Engineer explains the platform’s dual action: mechanically opening the biofilm while delivering antibiotics where they are needed.
Read the engineering featureThe Ineos Oxford Institute follows the collaboration, chronic-wound testing and next steps toward translating AURA technology into real-world treatment.
Read the AMR spotlightBBC News Arabic brings the story of ultrasound-responsive antibiotic delivery and the challenge of bacterial biofilms to a wider global audience.
View the BBC Arabic featureNo stories match this filter yet.
Research, partnerships and translation are moving in parallel. Explore the science behind AURAs or start a conversation with the team.